OBSOLETE: Keratoconus

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:156071
Who is this for?
Show terms as
1FDA treatments8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Keratoconus is a progressive eye disorder in which the normally round cornea (the clear, dome-shaped front surface of the eye) thins and begins to bulge outward into a cone shape. This abnormal curvature changes the way light enters the eye, causing distorted and blurred vision that cannot be fully corrected with standard eyeglasses. Keratoconus typically begins during puberty or the late teenage years and may progress through the twenties and thirties before stabilizing. It usually affects both eyes, though often asymmetrically. Key symptoms include progressive nearsightedness (myopia), irregular astigmatism, increased light sensitivity (photophobia), glare, and frequent changes in eyeglass prescriptions. In advanced cases, corneal scarring may develop, further impairing vision. Some patients experience episodes of acute corneal hydrops, where fluid suddenly enters the cornea causing pain and a sudden decrease in vision. Note: This Orphanet entry (ORPHA:156071) is classified as OBSOLETE, meaning it may have been reclassified, merged, or reorganized within the Orphanet nomenclature. Keratoconus itself remains a well-recognized clinical entity. Treatment options range from rigid gas-permeable contact lenses and specialty scleral lenses in mild-to-moderate cases, to corneal collagen cross-linking (CXL) to slow or halt disease progression, and corneal transplantation (penetrating or deep anterior lamellar keratoplasty) in advanced cases. Intracorneal ring segments (such as Intacs) may also be used to improve corneal shape. The etiology is considered multifactorial, involving both genetic susceptibility and environmental factors such as chronic eye rubbing and atopic disease.

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Juvenile

Begins in the teen years

Orphanet ↗NORD ↗

Treatments

1 available

Photrexa Viscous

riboflavin ophthalmic solution & ultraviolet A· Glaukos Corporation

Indicated for use in corneal collagen crosslinking in combination with the KXL System for the treatment of progressive keratoconus

No actively recruiting trials found for OBSOLETE: Keratoconus at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Keratoconus community →

No specialists are currently listed for OBSOLETE: Keratoconus.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Keratoconus.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: KeratoconusForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Keratoconus.

Start the conversation →

Latest news about OBSOLETE: Keratoconus

No recent news articles for OBSOLETE: Keratoconus.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about OBSOLETE: Keratoconus

What is OBSOLETE: Keratoconus?

Keratoconus is a progressive eye disorder in which the normally round cornea (the clear, dome-shaped front surface of the eye) thins and begins to bulge outward into a cone shape. This abnormal curvature changes the way light enters the eye, causing distorted and blurred vision that cannot be fully corrected with standard eyeglasses. Keratoconus typically begins during puberty or the late teenage years and may progress through the twenties and thirties before stabilizing. It usually affects both eyes, though often asymmetrically. Key symptoms include progressive nearsightedness (myopia), irre

How is OBSOLETE: Keratoconus inherited?

OBSOLETE: Keratoconus follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does OBSOLETE: Keratoconus typically begin?

Typical onset of OBSOLETE: Keratoconus is juvenile. Age of onset can vary across affected individuals.

What treatment and support options exist for OBSOLETE: Keratoconus?

1 patient support program are currently tracked on UniteRare for OBSOLETE: Keratoconus. See the treatments and support programs sections for copay assistance, eligibility, and contact details.